price close busi
catalyst beyond
spring upcom catalyst
sinc edit saw two gene therapi buyout roche/onc biib/nit
issu outlook aldr submit eptinezumab migrain prevent
approv said explor lumateperon major depress disord mdd
posit phase interim result adult classic congenit
adren hyperplasia ccah sign deal parkinson diseas
spray treatment-resist depress could bode well novel neuro
product rapastinel fail phase adjunct therapi mdd tabl
catalyst come tabl catalyst beyond
pimavanserin schizophrenia-inadequ respons phase data
enhanc data plan start two phase trial
pimavanserin mdd inadequ respons
rimegep acut treatment migrain new drug applic file
expect file competitor ubrogep accept file
sma type approv vumer ms gi data
gastrointestin toler data vumer vs tecfidera slate come
spinraza competitor spinal muscular atrophi type could approv
expect bioavail ba /pharmacokinet pk data
lumateperon phase top-lin data bipolar depress bpd
apart data two bpd phase trial fda advisori committe meet
lumateperon schizophrenia could held ahead action date
apart file elagolix via expect meet fda discuss
ccah recent posit interim result
zulresso approv phase open-label data bipolar depress
zulresso iv postpartum depress could approv action date phase
open-label part data bipolar depress could come
long-term data vy-aadc pd posterior-trajectori phase trial
could report long-term data phase trial vy-aadc advanc pd
includ data eight patient
asgct highli relev annual scientif meet companies/stock
american societi gene cell therapi meet washington dc
american academi neurolog meet philadelphia pa
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
estim studi complet date phase open-label safeti efficaci
studi pimavanserin
initi two phase trial pimavanserin mdd one us eu
potenti enrol complet pimavanserin phase
potenti data readout pimavanserin phase studi
hire chief offic cfo
treatment adult
parkinson diseas
inadequ respons
antidepress
estim studi complet date syneurx naben phase trial
estim studi complet date syneurx naben phase trial
top-lin result phase trial
potenti initi phase trial epidiolex
result phase trial minerva seltorex
patient mdd adjunct therapi
potenti start pivot studi evenamid
axsom meet fda discuss potenti regulatori path forward
top-line result phase trial minerva mdd
top-lin result phase elev trial vistagen
adjunct therapi estim primari complet date
adjunct therapi estim studi complet date sep-
adjunct therapi
announc todd young
employ end elena ridloff serv
suffici least next month per file
top-lin result phase trial minerva/mitsubishi tanab
potenti file nda schizophrenia
potenti fda advisori committe meet lumateperon
request prioriti review base track
design grant lumateperon treatment
result phase trial minerva seltorex
patient mdd adjunct therapi
potenti updat next step
updat allergan rapastinel program mdd
updat neuralstem
potenti initi phase trial reviva pharmaceut
develop reviva pharmaceut
potenti fda accept bla eptinezumab
potenti detail long-term data eptinezumab phase studi
hire chief commerci offic
potenti updat eptinezumab subcutan formul
potenti ex-u partner eptinezumab
form us fda nda plan
meet fda discuss content
potenti next step
announc rapastinel fail meet
primari endpoint three phase trial adjunct
treatment mdd
aldr announc ms elisabeth sandov
employ end
parkinson psychosi
expect last per earn press
potenti data phase trial
launch ramp teva ajovi fremanezumab
launch ramp lilli emgal galcanezumab
track commerci progress amgen/novarti aimovig erenumab
initi phase trial intranas
potenti nda file rimegep
potenti complet phase trial rimegep prevent
initi phase proof concept trial rimegep patient
addit data rimegep zydi oral dissolv tablet studi
potenti enrol complet trial troriluzol sca
complet addit toxicolog phase trial
updat eu strategi rimegep
result long-term safeti studi rimegep
acut treatment
acut treatment
acut treatment
acut treatment
acut treatment
result avail year end present
medic confer
teva receiv approv price product
aimovig emgal
other monthli
lilli receiv approv price product
aimovig teva ajovi
receiv approv aimovig set
list price per year aimovig
first anti-cgrp product approv fda
approv inject set price
estim studi complet date primari
trial initi john hopkin univers school
receiv feedback ema outlin
sever potenti pathway approv rimegep per
file updat
announc initi result open-label
long-term safeti studi rimegep estim primari
complet date estim studi complet date
addit data phase studi rimegep studi
addit data proof concept trial anxieti
potenti updat on-going phase trial
potenti fda accept bla aldr eptinezumab
result phase fortitude- trial reldesemtiv
potenti nda approv lilli lasmiditan
top-lin result phase studi brainstorm cell
potenti data phase trial
potenti initi phase trial genervon
discuss european medicin agenc path forward
launch ramp teva ajovi fremanezumab
acut treatment
acut treatment
prevent migrain
acut treatment
launch ramp lilli emgal galcanezumab
track commerci progress amgen/novarti aimovig erenumab
updat phase trial prana biotech
perform itf pharma tiglutik riluzol oral suspens
upcom scientif meet report
posit top-lin result trial
announc dose first patient
suffici fund oper per
american academi neurolog annual meet
philadelphia sunday may
announc submiss nda
lasmiditan us fda
result avail year end present
medic confer
teva receiv approv price product
aimovig emgal
other monthli
lilli receiv approv price product
aimovig teva ajovi
receiv approv aimovig set
list price per year aimovig
first anti-cgrp product approv fda
approv inject set price
itf pharma receiv approv expect
launch
initi phase trial ibudilast
conduct addit analys data phase studi neuraltu
potenti initi confirmatori phase studi
result potenti busi updat
estim studi complet date phase trial
potenti initi phase trial
potenti enrol complet phase trial biib/nit nsr-
follow-up data phase studi biib/nit nsr-rpgr
potenti preliminari data phase trial biib/nit nsr-rpgr
potenti close acquisit nightstar nite
potenti interim analys phase data aducanumab
potenti initi phase trial
potenti data phase trial
potenti exercis option acquir
sclerosi
potenti approv biosimilar adalimumab us
receiv posit feedback fda
phase plan ibudilast al
estim studi primari complet date
identifi alkerm announc
receiv payment review
announc acquisit nightstar
therapeut per share
announc enter
exclus option agreement acquir tm co ltd japan
per slide ioni present date
exercis option ioni develop
commerci base posit interim data readout
phase trial plan add addit cohort
studi potenti support registr
biib/samsung bioepi announc accept
bla adalimumab biosimilar fda
updat phase studi al
potenti five new asset enter clinic
potenti updat phase trial
potenti approv launch vumer
updat biogen/univers pennsylvania sma gene therapi
updates/furth detail phase studi alzheim
end
potenti initi phase studi evalu whether earli use
aducanumab prevent delay clinic onset ad
asset acquir
estim studi primari complet date
earn call said fda place ind
clinic hold updat call
eisai/biib present fuller data aaic meet chicago
ctad barcelona sub-group analys
present initi posit top-lin data
studi includ patient evid amyloid
patholog brain without subject cognit
complaint otherwis refer stage fda
draft guidanc treatment earli alzheim diseas
detail data phase trial dapirolizumab pegol upcom medic
potenti updat phase studi healthi volunt
impact roch ocrevu multipl sclerosi franchis
potenti busi develop activity/acquisit
novartis/avexi initi pediatr comer sma type
multi-n trial reach zolgensma
data novartis/avexi zolgensma pre-symptomat sma
type multi-n trial
complet novartis/avexi sma type phase trial strong
potenti addit data part roche/ptct sunfish
firefish trial risdiplam
potenti approv launch novartis/avexi zolgensma
potenti approv launch novartis/avexi zolgensma
type
type
type
earn press releas date biogen
announc acquir alg-
alivegen inc
receiv royalti ocrevu
enrol approxim patient six month
year age qualifi trial
time gene therapi
american academi neurolog annual meet
american academi neurolog annual meet
american academi neurolog annual meet
novarti announc fda accept nda
file prioriti review
novarti initi submiss mid-septemb anticip
complet file end
top-lin result phase studi firdaps
sma type
potenti data roche/ptct jewelfish trial
potenti approv launch novartis/avexi zolgensma
potenti preliminari data phase trial jnj/mgtx aav-rpgr
potenti approv merck kgaa nda mavenclad cladribin
updat potenti submiss market author applic
shanghai greenvalley pharmaceut china
potenti initi molecular therapeut chm
updat on-going pivot trial roch s/ptct
sma type
potenti updat on-going phase studi roch s/spark spk-
chm
effect generic copaxon brand ms product
potenti path forward sma type
preclin data combin
american associ cancer research annual meet
potenti present data american societi
initi phase studi avelumab
initi phase poc studi
potenti data readout bridg bioavail ba pk studi
select next clinic candid
type
mild moder
type
type
agit alzheim
diseas schizophrenia
annual cure sma confer anaheim ca
novarti submit ema earli
fda accept nda merck kgaa mavenclad
atlanta georgia
neoadjuv proof mechan trial initi
announc dose first six patient
studi expect enrol healthi adult volunt
expect complet dose patient
last least one year
file
updat agit patient probabl alzheim diseas
program lumateperon
expect top line data phase trial lumateperon
expect top line data phase trial lumateperon
potenti fda advisori committe meet lumateperon
initi phase clinic trial
initi proof-of-concept poc trial lumateperon mdd
expect top line data phase trial lumateperon
adjunct therapi lithium valproat
updat agit patient probabl alzheim diseas
program lumateperon
potenti data open-label long-term safeti switch studi
treatment agit
patient probabl
announc stop studi
futil
treatment agit
patient probabl
estim primari complet date estim
estim primari complet date estim
potenti adcom meet ahead fda action date
announc posit top-line data phase
studi patient parkinson diseas
last per press releas date
estim primari complet date estim
announc stop studi
futil
announc favor result
second part open-label safeti switch studi studi
initi phase trial restorbio combin rapalog
parkinson diseas
data readout part open-label portion phase trial
bipolar depress
potenti snda approv allergan vraylar cariprazin
top-line result phase trial minerva mdd
end
announc accept snda fda
pdufa action date may
initi two phase trial acadia pimavanserin mdd one us
eu
result phase trial minerva seltorex
patient mdd adjunct therapi
potenti file nda schizophrenia
result phase trial minerva seltorex
patient mdd adjunct therapi
updat allergan rapastinel program mdd
potenti updat next step
potenti nda file opicapon
potenti meet fda discuss result phase studi
adult
provid long-term data phase trial vy-aadc includ
data patient dose posterior-trajectori method
potenti initi phase studi pediatr
potenti supplement nda file elagolix
potenti updat phase trial novel inhibitor
select lead clinic candid friedreich ataxia program
collabor
enrol pivot phase begin vy-aadc
potenti data phase studi adult
data pivot phase studi phase extens studi
inadequ respons
antidepress
announc rapastinel fail meet
primari endpoint three phase trial adjunct
treatment mdd
form us fda nda plan
meet fda discuss content
potenti next step
receiv mileston royalti approv
month enrol complet month
announc posit interim result
data analysi phase trial t-forc gold ingrezza
long-term data vy-aadc phase cohort
enrol statu phase trial vy-aadc
initi larger clinic studi emalex bioscienc ecopipam
potenti top-lin data phase trial lundbeck/prexton foliglurax
present posit top-line data phase studi tildacerfont
congenit adren hyperplasia annual meet
endocrin societi
potenti data myovant/takeda phase liberti trial relugolix
dose first patient cohort axov scienc phase dose
escal studi sunrise-pd axo-lenti-pd
top-line data intec pharma ap-cd/ld phase studi
potenti updat on-going phase studi
furher data axov scienc phase dose escal studi
sunrise-pd axo-lenti-pd
updat allergan uliprist acet
announc phase t-forc gold
studi valbenazin pediatr tourett syndrom fail
last least next month per file
announc initi trial us
axon announc interim-data cohort
allergan receiv complet respons letter
us fda abl approv uliprist acet
nda current form allergan plan meet fda
discuss comment next step
data readout part open-label portion phase archway trial
bipolar depress
data readout phase biomark studi
potenti launch zulresso brexanolon iv approv
announc fda extend zulresso
pdufa date final rem
nda approv post-dea drug enforc
plan meet fda develop path
potenti updat addit scientif advic european medicin
agenc brexanolon
potenti initi monotherapi mainten studi
potenti snda approv allergan vraylar cariprazin
initi phase trial acadia pimavanserin adjunct therapi
top-line result phase trial minerva mdd
data part phase magnolia studi marinu
full data phase amarylli studi
expect top line data phase trial
expect top line data phase trial
result phase trial minerva seltorex
patient mdd adjunct therapi
axsom meet fda discuss potenti regulatori path forward
top-lin result phase trial vistagen
result phase trial minerva seltorex
patient mdd adjunct therapi
result phase trial minerva seltorex
patient insomnia
potenti updat next step
updat allergan rapastinel program mdd
last per press releas date
announc accept snda fda
pdufa action date may
announc posit result part
announc posit result interim
analysi amarylli studi
expect complet patient enrol
estim primari complet date estim
estim primari complet date estim
form us fda nda plan
meet fda discuss content
potenti next step
announc rapastinel fail meet
primari endpoint three phase trial adjunct
treatment mdd
updat neuralstem
expect top line data phase trial lumateperon
adjunct therapi lithium valproat
data phase part simplic studi
enrol patient evalu efficaci azeliragon patient
alzheim diabet
updat formal guidanc receiv scientif advic
work parti sawp european medicin agenc ema
multi-region phase studi
provid long-term data phase trial vy-aadc includ
month data patient dose posterior-trajectori method
provid long-term safeti biomark motor function qualiti life
data cohort on-going phase trial vy-aadc
progress research activ abbvie/tau program compani
identifi five antibodi inclus toward develop
advanc monogen form al toward
enrol pivot phase begin vy-aadc
updat abbvie/vygr alpha-synuclein program
long-term data vy-aadc phase cohort
initi human studi
enrol statu phase trial vy-aadc
estim primari complet date estim
alzheim diseas
last march per file
al huntington
estim studi primari complet date
month enrol complet month
last per press releas date
dose first patient cohort axov scienc phase dose
escal studi sunrise-pd axo-lenti-pd
data axov scienc phase dose escal studi
sunrise-pd axo-lenti-pd
potenti updat on-going phase studi
compani report clinicaltri gov canaccord genuiti estim updat
axon announc interim-data cohort
announc initi trial us
treatment adult
parkinson diseas
inadequ respons
antidepress
agit aggress
adjunct therapi estim primari complet date
adjunct therapi estim studi complet date sep-
adjunct therapi
studi evalu efficaci safeti approxim
femal age year
adjunct therapi estim studi complet date jun-
adjunct therapi estim primari complet date
announc todd young
employ end elena ridloff serv
suffici least next month per file
estim studi complet date phase open-label safeti efficaci
studi pimavanserin
initi two phase trial pimavanserin mdd one us eu
potenti enrol complet pimavanserin phase
potenti data readout pimavanserin phase studi
estim studi complet date phase open-label trial
initi phase trial trofinetid
potenti enrol complet pimavanserin phase advanc
potenti interim data-readout phase trial harmoni
estim studi complet date phase trial harmoni
potenti final result phase trial harmoni pimavanserin
estim studi complet date phase open-label safeti
toler studi pimavanserin
potenti nda file trofinetid
hire chief offic cfo
estim studi complet date syneurx naben phase trial
estim studi complet date syneurx naben phase trial
top-lin result phase trial
potenti initi phase trial epidiolex
result phase trial minerva seltorex
patient mdd adjunct therapi
potenti start pivot studi evenamid
axsom meet fda discuss potenti regulatori path forward
top-line result phase trial minerva mdd
top-lin result phase elev trial vistagen
top-lin result phase trial minerva/mitsubishi tanab
potenti file nda schizophrenia
potenti fda advisori committe meet lumateperon
request prioriti review base track
design grant lumateperon treatment
result phase trial minerva seltorex
patient mdd adjunct therapi
estim studi complet date allergan phase trial
lumateperon fda action date schizophrenia
potenti top-lin data phase star studi newron
estim studi complet date phase debut studi lundbeck lu
estim studi complet date phase trial
estim studi complet date anavex phase trial
estim studi complet date syneurx naben phase trial
potenti updat next step
announc fda accept nda
lumateperon treatment schizophrenia
form us fda nda plan
meet fda discuss content
potenti next step
announc rapastinel fail meet
primari endpoint three phase trial adjunct
treatment mdd
updat allergan rapastinel program mdd
estim studi complet date phase trial sunovion
estim studi complet date phase studi lundbeck lu
estim studi complet date phase trial mediti pharma mp-
estim studi complet date phase trial astrazeneca
updat neuralstem
potenti initi phase trial reviva pharmaceut
develop reviva pharmaceut
compani report clinicaltri gov canaccord genuiti estim updat
parkinson psychosi
adjunct therapi estim primari complet date
potenti fda accept bla eptinezumab
initi first-in-human studi
end
potenti launch eptinezumab
potenti payment teva approv bla eptinezumab
potenti data first-in-human studi
potenti detail long-term data eptinezumab phase studi
hire chief commerci offic
potenti updat eptinezumab subcutan formul
potenti ex-u partner eptinezumab
potenti data phase trial
estim studi complet date phase trial allergan atogep
daili
estim studi complet date phase trial allergan atogep
daili
estim studi complet date phase trial allergan atogep
twice daili
launch ramp teva ajovi fremanezumab
launch ramp lilli emgal galcanezumab
monoclon antibodi target pituitari
adenyl cyclase-activ
prevent migrain
aldr announc submiss bla fda
per aldr european patent settlement global licens
agreement teva
aldr announc ms elisabeth sandov
employ end
expect last per earn press
result avail year end present
medic confer
teva receiv approv price product
aimovig emgal
other monthli
lilli receiv approv price product
aimovig teva ajovi
receiv approv aimovig set
list price per year aimovig
first anti-cgrp product approv fda
approv inject set price
track commerci progress amgen/novarti aimovig erenumab
compani report clinicaltri gov canaccord genuiti estim updat
initi phase trial intranas
potenti nda file rimegep
potenti complet phase trial rimegep prevent
initi phase proof concept trial rimegep patient
initi phase trial verdiperstat
potenti approv sublingu riluzol al
potenti top-line data phase trial rimegep prevent
top-line data phase trial
potenti enrol complet trial troriluzol mild
potenti enrol complet trial troriluzol ocd
potenti enrol complet trial troriluzol gad
estim studi complet date phase trial troriluzol gad
acut treatment
acut treatment
acut treatment
mild moder
end mild moder
acut treatment
mild moder
futil analysi phase trial troriluzol mild moder
addit data rimegep zydi oral dissolv tablet studi
potenti enrol complet trial troriluzol sca
complet addit toxicolog phase trial
estim studi complet date phase trial troriluzol
estim studi complet date primari
trial initi john hopkin univers school
announc receiv fda may
proceed letter phase trial
announc fda accept
nda file treatment al action
date
estim studi complet date primari
initi trial phase trial success
announc enrol first patient
trial expect enrol patient site
estim studi complet date phase trial troriluzol
estim studi complet date phase trial troriluzol
potenti launch rimegep
updat eu strategi rimegep
result long-term safeti studi rimegep
addit data phase studi rimegep studi
addit data proof concept trial anxieti
potenti updat on-going phase trial
potenti fda accept bla aldr eptinezumab
result phase fortitude- trial reldesemtiv
estim studi complet date phase trial denali
estim studi complet date phase trial amylyx
allergan ubrogep action date acut treatment migrain
potenti nda approv lilli lasmiditan
top-lin result phase studi brainstorm cell
potenti data phase trial
acut treatment
acut treatment
acut treatment
acut treatment
acut treatment
prevent migrain
acut treatment
acut treatment
announc enrol first patient trial
receiv feedback ema outlin
sever potenti pathway approv rimegep per
file updat
announc initi result open-label
long-term safeti studi rimegep estim primari
complet date estim studi complet date
upcom scientif meet report
posit top-lin result trial
announc dose first patient
suffici fund oper per
american academi neurolog annual meet
philadelphia sunday may
announc accept nda
ubrogep us fda
announc submiss nda
lasmiditan us fda
result avail year end present
medic confer
potenti initi phase trial genervon
estim studi complet date phase trial allergan atogep
daili
estim studi complet date phase trial allergan atogep
daili
potenti launch allergan ubrogep
estim studi complet date phase trial allergan atogep
twice daili
potenti launch allergan atogep
discuss european medicin agenc path forward
launch ramp teva ajovi fremanezumab
acut treatment
launch ramp lilli emgal galcanezumab
track commerci progress amgen/novarti aimovig erenumab
updat phase trial prana biotech
perform itf pharma tiglutik riluzol oral suspens
initi phase trial ibudilast
conduct addit analys data phase studi neuraltu
compani report clinicaltri gov canaccord genuiti estim updat
teva receiv approv price product
aimovig emgal
other monthli
lilli receiv approv price product
aimovig teva ajovi
receiv approv aimovig set
list price per year aimovig
first anti-cgrp product approv fda
approv inject set price
itf pharma receiv approv expect
launch
receiv posit feedback fda
phase plan ibudilast al
potenti initi confirmatori phase studi
result potenti busi updat
estim studi complet date phase trial
potenti initi phase trial
potenti enrol complet phase trial biib/nit nsr-
follow-up data phase studi biib/nit nsr-rpgr
potenti preliminari data phase trial biib/nit nsr-rpgr
potenti close acquisit nightstar nite
potenti result pivot phase trial passport
potenti approv nda vumer fda
one-year follow-up data phase studi biib/nit nsr-rpgr
vixotrigin initi phase program trigemin neuralgia
end
potenti interim analys phase data aducanumab
potenti initi phase trial
potenti data phase trial
potenti exercis option acquir
estim studi primari complet date
identifi alkerm announc
receiv payment review
announc acquisit nightstar
therapeut per share
potenti file data posit
alks/biib announc accept nda
diroximel fumar regulatori pathway
pdufa action date
enrol phase studi small fiber neuropathi per
announc enter
exclus option agreement acquir tm co ltd japan
per slide ioni present date
potenti approv biosimilar adalimumab us
updat phase studi al
potenti five new asset enter clinic
potenti updat phase trial
potenti approv launch vumer
final data phase trial aducanumab
full data phase studi
estim studi complet date phase trial passport
end
estim studi complet date phase trial
sclerosi
exercis option ioni develop
commerci base posit interim data readout
phase trial plan add addit cohort
studi potenti support registr
biib/samsung bioepi announc accept
bla adalimumab biosimilar fda
asset acquir
estim studi primari complet date
identifi announc
enrol complet trial
associ
estim studi complet date phase affin trial
data phase affin studi opicinumab
potenti data phase trial biib/nit
estim studi complet date phase trial natalizumab
estim studi complet date phase trial tysabri
estim studi primari complet date
clinicaltri gov identifi
announc enrol first patient studi
top-lin result phase trial
one-year follow-up data phase studi biib/nit nsr-rpgr
estim studi complet date phase trial eisai
estim studi complet date phase trial eisai
estim studi complet date phase trial
estim studi complet date phase spirit trial
estim studi complet date phase trial
estim studi complet date phase trial engag
estim studi complet date phase trial emerg
estim studi complet date phase studi
estim studi complet date phase trial
estim studi complet date phase evolv studi
updat biogen/univers pennsylvania sma gene therapi program
updates/furth detail phase studi alzheim
potenti initi phase studi evalu whether earli use
aducanumab prevent delay clinic onset ad
studi design assess clinic relev
earn call said fda place ind
clinic hold updat call
eisai/biib present fuller data aaic meet chicago
ctad barcelona sub-group analys
present initi posit top-lin data
studi includ patient evid amyloid
patholog brain without subject cognit
complaint otherwis refer stage fda
draft guidanc treatment earli alzheim diseas
detail data phase trial dapirolizumab pegol upcom medic
potenti updat phase studi healthi volunt
earn press releas date biogen
announc acquir alg-
alivegen inc
impact roch ocrevu multipl sclerosi franchis
potenti busi develop activity/acquisit
receiv royalti ocrevu
novartis/avexi initi pediatr comer sma type
multi-n trial reach zolgensma
type
data novartis/avexi zolgensma pre-symptomat sma
type multi-n trial
complet novartis/avexi sma type phase trial strong
potenti addit data part roche/ptct sunfish
firefish trial risdiplam
potenti approv launch novartis/avexi zolgensma
potenti approv launch novartis/avexi zolgensma
top-lin result phase studi firdaps
sma type
potenti data roche/ptct jewelfish trial
potenti approv launch novartis/avexi zolgensma
potenti preliminari data phase trial jnj/mgtx aav-rpgr
potenti data roche/ptct jewelfish trial
estim studi complet date phase trial aztherapi
type
type
type
type
estim studi complet date novartis/avexi zolgensma avxs-
potenti studi complet novarti branaplam phase studi
potenti studi complet phase trial asclepio novarti
potenti studi complet phase trial asclepio ii novarti
potenti nda file roche/ptct risdiplam sma
estim studi complet date phase trial denali
type
potenti approv merck kgaa nda mavenclad cladribin
enrol approxim patient six month
year age qualifi trial
time gene therapi
american academi neurolog annual meet
american academi neurolog annual meet
american academi neurolog annual meet
novarti announc fda accept nda
file prioriti review
novarti initi submiss mid-septemb anticip
complet file end
annual cure sma confer anaheim ca
novarti submit ema earli
annual congress world muscl societi
fda accept nda merck kgaa mavenclad
updat potenti submiss market author applic
shanghai greenvalley pharmaceut china
potenti initi molecular therapeut chm
estim studi complet date phase trial
potenti studi complet phase trial sakura novarti
estim studi complet date roche/ptct
sma type
estim studi complet date phase trial roch gantenerumab
estim studi complet date roche/ptct
sma type
estim studi complet date novartis/avexi zolgensma avxs-
potenti approv roche/ptct risdiplam sma type
estim studi complet date trial
estim studi complet date phase trial roch
estim studi complet date phase trial solanezumab
mild moder
mild moder
type
type
type
estim studi complet date phase trial roch
estim studi complet date phase trial roch gantenerumab
prodrom mild ad
estim studi complet date phase trial roch gantenerumab
estim studi complet date novartis/avexi zolgensma avxs-
pre-symptomat sma type multi-n trial sprint
type
estim studi complet date phase trial novarti
estim studi complet date phase trial novarti
patient enrol enrol approxim
patient copi less
six week age pre-symptomat time gene
updat on-going pivot trial roch s/ptct
sma type
potenti updat on-going phase studi roch s/spark spk-
chm
effect generic copaxon brand ms product
potenti path forward sma type
compani report clinicaltri gov canaccord genuiti estim updat
type
type
preclin data combin
american associ cancer research annual meet
potenti present data american societi
initi phase studi avelumab
initi phase poc studi
potenti data readout bridg bioavail ba pk studi
potenti ex-u partner japan
initi registr trial
preliminari data readout phase combin trial
data readout phase combin trial
data phase poc mechan studi
data phase poc tripl combin trial
avelumab
potenti nda file
select next clinic candid
initi registr trial
potenti nda file
atlanta georgia
agit alzheim
diseas schizophrenia
agit alzheim
diseas schizophrenia
agit alzheim
diseas schizophrenia
agit alzheim
diseas schizophrenia
pancreat cancer
pancreat cancer
neoadjuv proof mechan trial initi
announc dose first six patient
studi expect enrol healthi adult volunt
expect complet dose patient
mechan action
last least one year
file
estim studi complet date phase trial avanir
top-lin result axsom phase trial
estim studi complet date phase trial avanir
estim studi complet date phase trial lundbeck
updat agit patient probabl alzheim diseas
program lumateperon
compani report clinicaltri gov canaccord genuiti estim updat
agit alzheim
agit alzheim
agit alzheim
agit alzheim
treatment agit
patient probabl
announc posit data interim
futil analysi phase trial
announc stop studi
futil
expect top line data phase trial lumateperon
expect top line data phase trial lumateperon
potenti fda advisori committe meet lumateperon
lumateperon action date pdufa schizophrenia
potenti file nda lumateperon bipolar depress
estim studi complet date phase trial
initi clinic trial
later
initi phase clinic trial
initi proof-of-concept poc trial lumateperon mdd
expect top line data phase trial lumateperon
adjunct therapi lithium valproat
updat agit patient probabl alzheim diseas
program lumateperon
opioid substanc
use disord pain
treatment agit
patient probabl
potenti data open-label long-term safeti switch studi
initi phase trial restorbio combin rapalog
parkinson diseas
data readout part open-label portion phase trial
bipolar depress
estim primari complet date estim
estim primari complet date estim
potenti adcom meet ahead fda action date
announc complet submiss nda
lumateperon treatment schizophrenia fda
announc accept nda fda
announc posit top-line data phase
studi patient parkinson diseas
last per press releas date
estim primari complet date estim
announc stop studi
futil
announc favor result
second part open-label safeti switch studi studi
end
potenti snda approv allergan vraylar cariprazin
top-line result phase trial minerva mdd
initi two phase trial acadia pimavanserin mdd one us
eu
result phase trial minerva seltorex
patient mdd adjunct therapi
potenti file nda schizophrenia
result phase trial minerva seltorex
patient mdd adjunct therapi
estim studi complet date allergan phase trial
estim studi complet date phase trial
potenti launch allergan vraylar cariprazin
updat allergan rapastinel program mdd
potenti updat next step
inadequ respons
antidepress
compani report clinicaltri gov canaccord genuiti estim updat
announc accept snda fda
pdufa action date may
announc rapastinel fail meet
primari endpoint three phase trial adjunct
treatment mdd
form us fda nda plan
meet fda discuss content
potenti next step
potenti nda file opicapon
potenti meet fda discuss result phase studi
adult
provid long-term data phase trial vy-aadc includ
data patient dose posterior-trajectori method
potenti initi phase studi pediatr
potenti supplement nda file elagolix
potenti initi pivot phase trial adult
top-lin data t-forc platinum studi ingrezza
estim studi complet date phase cohort trial
potenti updat phase trial novel inhibitor
select lead clinic candid friedreich ataxia program
collabor
enrol pivot phase begin vy-aadc
potenti data phase studi adult
estim studi complet date phase open-label t-forc gold
trial pediatr patient ingrezza
potenti opicapon launch us
potenti complet phase enrol vy-
receiv mileston royalti approv
month enrol complet month
announc posit interim result
announc first patient dose phase
clinicaltri gov identifi month
recruit patient trial
potenti data readout phase program vy-
data pivot phase studi phase extens studi
data analysi phase trial t-forc gold ingrezza
long-term data vy-aadc phase cohort
enrol statu phase trial vy-aadc
initi larger clinic studi emalex bioscienc ecopipam
potenti top-lin data phase trial lundbeck/prexton foliglurax
present posit top-line data phase studi tildacerfont
congenit adren hyperplasia annual meet
endocrin societi
potenti data myovant/takeda phase liberti trial relugolix
dose first patient cohort axov scienc phase dose
escal studi sunrise-pd axo-lenti-pd
top-line data intec pharma ap-cd/ld phase studi
estim studi complet date phase trial safeti efficaci
estim studi complet date phase trial artist teva
potenti data myovant/takeda phase liberti trial relugolix
start registr trial dipraglur
potenti data phase studi primros obseva
potenti nda file myovant/takeda relugolix
estim studi complet date phase trial
potenti updat on-going phase studi
furher data axov scienc phase dose escal studi
sunrise-pd axo-lenti-pd
potenti data phase studi primros obseva linzagolix
potenti data myovant/takeda phase trial spirit
estim studi complet date phase trial diurnal chronocort
announc phase t-forc gold
studi valbenazin pediatr tourett syndrom fail
last least next month per file
announc initi trial us
axon announc interim-data cohort
estim studi complet date phase trial
top-line result therapix bioscienc phase trial
estim studi complet date phase trial impax
estim studi complet date phase trial bayer vilaprisan
updat allergan uliprist acet
compani report clinicaltri gov canaccord genuiti estim updat
allergan receiv complet respons letter
us fda abl approv uliprist acet
nda current form allergan plan meet fda
discuss comment next step
data readout part open-label portion phase archway trial
bipolar depress
data readout phase biomark studi
potenti launch zulresso brexanolon iv approv
data readout phase multipl ascend dose trial
top-line result phase trial essenti tremor
top-line result phase studi patient earli
estim studi complet date phase mountain trial sage-
mdd
data phase mountain studi mdd
plan meet fda develop path
potenti updat addit scientif advic european medicin
agenc brexanolon
potenti initi monotherapi mainten studi
estim studi complet date phase rainforest trial sage-
mdd patient co-morbid insomnia
data phase rainforest studi mdd patient
data long-term retreat phase studi shorelin
potenti snda approv allergan vraylar cariprazin
initi phase trial acadia pimavanserin adjunct therapi
top-line result phase trial minerva mdd
data part phase magnolia studi marinu
full data phase amarylli studi
announc fda extend zulresso
pdufa date final rem
nda approv post-dea drug enforc
last per press releas date
announc accept snda fda
pdufa action date may
announc posit result part
announc posit result interim
analysi amarylli studi
expect top line data phase trial
expect top line data phase trial
result phase trial minerva seltorex
patient mdd adjunct therapi
axsom meet fda discuss potenti regulatori path forward
top-lin result phase trial vistagen
result phase trial minerva seltorex
patient mdd adjunct therapi
result phase trial minerva seltorex
patient insomnia
estim studi complet date allergan phase trial
potenti file nda lumateperon bipolar depress
potenti launch allergan vraylar cariprazin
potenti updat next step
updat allergan rapastinel program mdd
updat neuralstem
expect top line data phase trial lumateperon
adjunct therapi lithium valproat
compani report clinicaltri gov canaccord genuiti estim updat
expect complet patient enrol
estim primari complet date estim
estim primari complet date estim
form us fda nda plan
meet fda discuss content
potenti next step
announc rapastinel fail meet
primari endpoint three phase trial adjunct
treatment mdd
estim primari complet date estim
data phase part simplic studi
enrol patient evalu efficaci azeliragon patient
alzheim diabet
updat formal guidanc receiv scientif advic
work parti sawp european medicin agenc ema
data phase part simplic studi
multi-region phase studi
compani report clinicaltri gov canaccord genuiti estim updat
alzheim diseas
last march per file
provid long-term data phase trial vy-aadc includ
month data patient dose posterior-trajectori method
provid long-term safeti biomark motor function qualiti life
data cohort on-going phase trial vy-aadc
progress research activ abbvie/tau program compani
identifi five antibodi inclus toward develop
advanc monogen form al toward
enrol pivot phase begin vy-aadc
potenti complet phase enrol vy-aadc
potenti data readout phase program vy-aadc
updat abbvie/vygr alpha-synuclein program
long-term data vy-aadc phase cohort
initi human studi
enrol statu phase trial vy-aadc
dose first patient cohort axov scienc phase dose
escal studi sunrise-pd axo-lenti-pd
data axov scienc phase dose escal studi
sunrise-pd axo-lenti-pd
potenti updat on-going phase studi
compani report clinicaltri gov canaccord genuiti estim updat
al huntington
estim studi primari complet date
month enrol complet month
announc first patient dose phase
clinicaltri gov identifi month
recruit patient trial
last per press releas date
axon announc interim-data cohort
announc initi trial us
